IDH1 and central nervous system cancer: Whether IDH-mutant gliomas or tumors with inherently lower immune infiltration (e.g., proneural) are inherently less responsive to immunotherapy due to their “cold” phenotype is hypothesized, but remains to be demonstrated clinically.